Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.59 |
| ▸ | RAF1 | P04049 | 13/20 | 0.50 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | RET | P07949 | 3/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.49 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.49 |
| ▸ | TTK | P33981 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548256 | 0.86 | RAF1 (0.67) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL29733289 | 0.86 | RAF1 (0.67) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL29746661 | 0.83 | KDR (0.68) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL15114776 | 0.83 | KDR (0.68) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL549118 | 0.83 | RAF1 (0.65) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL30877064 | 0.82 | BRAF (0.42) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL14481108 | 0.81 | RAF1 (0.60) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL16628088 | 0.80 | RAF1 (0.75) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL14714846 | 0.79 | KDR (0.62) | KDRRAF1BRAFEPHX2RET | |
| SCHEMBL31323421 | 0.78 | RAF1 (0.54) | KDRRAF1BRAFEPHX2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665720-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4611901-A1 | RET-LDD PROTEIN DEGRADERS | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4611900-A1 | RET-LDD PROTEIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025129116-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2024173832-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024097989-A1 | RET-LDD PROTEIN DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |